Why IMU is a multi multi bagger, page-20463

@Watmighthavben

Hence as @fourdollars has suggested it was probably unwise of LC to not pursue the out licensing or commercialisation of Her Vaxx in the latter stages of 2021 if not 2022.

I reckon she did, and failed. That's why she came back sheepishly with the "crowded space" commentary.

But of perhaps greater concern is the fact they post negative comments about a clearly safe and efficacious drug such as Her Vaxx, which has demonstrated extension of life close to six months over and above the standard of care (chemotherapy). By inference for anyone in their right mind to suggest the families of those administered with Her Vaxx were disappointed their relatives and close kin lived an extra six months than they otherwise would have, had they not taken Her Vaxx, is not left of centre, but an attempt to defy reality.

What a pathetic cheap shot.

HER-Vaxx did not meet the required statistical hurdle for efficacious. If it had, the trial would have progressed.

If it was as good as you claim, what would you tell the families (since you have such a "right mind" of course) of those that were slated for the trial but then denied HER-Vaxx due to "ethical considerations". I've posed this question at least 10 times, but no one has been able to even proffer a theory. If HER-Vaxx was so safe and so effective, why would you deny it to those that would have made up the balance of the planned 68 cohort?

And why, if HER-Vaxx is so safe and so effective has IMU deprioritsed it?